BDBM253979 US10189849, Compound 33::US10927120, Compound 33::US9464092, SSS::US9527857, SSS::US9957276, Compound 33

SMILES O=C1NCC2(CCCC2)n2c1cc1cnc(Nc3ccc(nn3)N3CCOCC3)nc21

InChI Key InChIKey=NLHJLMBCNCNHRL-UHFFFAOYSA-N

Data  12 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 12 hits for monomerid = 253979   

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM253979(US9464092, SSS | US9527857, SSS | US10189849, Comp...)
Affinity DataIC50: 2nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif....More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2017
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM253979(US9464092, SSS | US9527857, SSS | US10189849, Comp...)
Affinity DataIC50: 2.28E+3nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif....More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2017
Entry Details
Go to US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM253979(US9464092, SSS | US9527857, SSS | US10189849, Comp...)
Affinity DataIC50: 1.88E+3nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif....More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2017
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM253979(US9464092, SSS | US9527857, SSS | US10189849, Comp...)
Affinity DataIC50: 2.28E+3nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2017
Entry Details
Go to US Patent

TargetCyclin-A1/Cyclin-dependent kinase 2(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253979(US9464092, SSS | US9527857, SSS | US10189849, Comp...)
Affinity DataIC50: 1.88E+3nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2017
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM253979(US9464092, SSS | US9527857, SSS | US10189849, Comp...)
Affinity DataIC50: 2nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2017
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM253979(US9464092, SSS | US9527857, SSS | US10189849, Comp...)
Affinity DataIC50: 2.28E+3nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/25/2018
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM253979(US9464092, SSS | US9527857, SSS | US10189849, Comp...)
Affinity DataIC50: 2nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/25/2018
Entry Details
Go to US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM253979(US9464092, SSS | US9527857, SSS | US10189849, Comp...)
Affinity DataIC50: 1.88E+3nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/25/2018
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM253979(US9464092, SSS | US9527857, SSS | US10189849, Comp...)
Affinity DataIC50: 5.05E+4nMAssay Description:Kinase enzymatic reactions were performed in 384-well microplates using a 12-channel Caliper LabChip instrument as a detection device. The enzymatic ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM253979(US9464092, SSS | US9527857, SSS | US10189849, Comp...)
Affinity DataIC50: 5.05E+4nMAssay Description:Kinase enzymatic reactions were performed in 384-well microplates using a 12-channel Caliper LabChip instrument as a detection device. The enzymatic ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/23/2020
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM253979(US9464092, SSS | US9527857, SSS | US10189849, Comp...)
Affinity DataIC50: 5.05E+4nMAssay Description:For the measurement of CDK2/cyclinE activity, enzyme (0.22 nM) was incubated with 100 mM ATP and the phosphoacceptor substrate peptide (1 mM) for one...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
Go to US Patent